When it comes to buying an experienced cancer drug specialist, a bidding war is naturally expected. But in the case of Pfizer’s $11 billion deal for Array BioPharma, that didn’t happen. Still, it didn ...
Until recently phased array radar has been very expensive, used only for military applications where the cost of survival weighs in the balance. With the advent of low-cost microwave devices and ...
ARRY is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of ARRY shares has decreased $0.09 since the market last closed. This is a 1.17% ...
Array Technologies, Inc. (NASDAQ:ARRY) is among the 11 Most Undervalued Renewable Energy Stocks to Invest In. On March 6, UBS lowered the firm’s price target on Array Technologies, Inc. (NASDAQ:ARRY) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results